<DOC>
	<DOC>NCT01976364</DOC>
	<brief_summary>This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.</brief_summary>
	<brief_title>Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Previous participation in qualifying PsA study involving tofacitinib Time from End of Study visit of qualifying study is &gt;3 months. Pregnant female, breastfeeding female or female of childbearing potential unwilling or unable to use highly effective birth control for duration of study and one ovulatory cycle thereafter.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tofacitinib</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>CP-690550</keyword>
	<keyword>Jak-inhibitor</keyword>
	<keyword>oral treatment</keyword>
	<keyword>psoriasis</keyword>
	<keyword>OPAL BALANCE</keyword>
	<keyword>moderate</keyword>
	<keyword>sever</keyword>
	<keyword>pruritus</keyword>
	<keyword>itch</keyword>
	<keyword>DLQI</keyword>
</DOC>